Our MIT CCSB Tumor Cell Networks Center is directed toward achieving three overarching objectives: Objective 1 - Cancer Research: advance the development and application of new systems biology approaches to cancer research in three significant scientific areas (mitogenesis, migration, and DNA damage/repair) and improve corresponding approaches for discovery and use of cancer therapies;Objective 2 - Education: train a new generation of young research leaders comfortable at the interdisciplinary interface between experimental molecular/cell biology and quantitative modeling in key areas of basic and applied cancer research;Objective 3 - Collaboration and Outreach: serve the general cancer biology community by acting as a collaborative partner that brings new ideas and methods to a wide community of investigators regardless of institutional affiliation. A central thread integrating our experiment and modeling efforts is a paradigmatic 'cue-signal-response'framework for probing and modeling the regulation of tumor cell phenotypes critical to tumor cell biology.
We aim to develop and make available to the cancer biology community successful models of three distinct but inter-related classes of models: 'Cell Response'models, capable of predicting how cellular phenotypes are executed by biophysical molecular processes;'Signal-Response'models, capable of predicting how cellular responses are regulated by information carried by intracellular signaling pathways;and 'Cue-Signal'models, capable of predicting what intracellular signals are generated by environmental stimuli and therapeutic agents in the context of specific genotypes. The construction and testing of all three classes of models is currently underway and linked to three important problems in cancer biology and therapy: (a) cancer progression via dysregulation of mitogenic signaling pathways downstream of receptor tyrosine kinases;(b) cancer progression via inappropriate cell migration processes that promote invasive and metastatic behavior;and (c) cancer treatment via molecular pharmaceuticals including chemotherapeutics and targeted inhibitors. Our Education and Outreach activities include participation in regular meetings of a student/postdoc/faculty systems biology community at MIT as well as dedicated seminars and retreats, offering of curricular subjects, short courses, conference sessions, and symposia related to cancer systems biology. We also are proactive in making our data, models, and publications available on our website, and in collaborative interactions with cancer biology investigators at other institutions.

Public Health Relevance

The purpose of the NCI CCSB initiative as stated in RFA-CA-09-011 is: to stimulate the development and apphcation of the integrative systems approaches and mathematical/computational modeling to cancer research... specifically in the areas of (a) cancer biology;(b) experimental therapeutics;(c) early interventions;and (d) cancer susceptibihty. Our MIT CCSB Tumor Cell Networks Center focus will fall centrally within Area (a), cancer biology, with intersection into Area (b), experimental therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA112967-09
Application #
8460954
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (J1))
Program Officer
Gallahan, Daniel L
Project Start
2004-09-30
Project End
2015-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
9
Fiscal Year
2013
Total Cost
$2,246,380
Indirect Cost
$900,737
Name
Massachusetts Institute of Technology
Department
Internal Medicine/Medicine
Type
Schools of Arts and Sciences
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Kulkarni, Madhura; Tan, Tuan Zea; Syed Sulaiman, Nurfarhanah Bte et al. (2018) RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9:14175-14192
Oudin, Madeleine J; Barbier, Lucie; Schäfer, Claudia et al. (2017) MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer. Mol Cancer Ther 16:143-155
Bruno, Peter M; Liu, Yunpeng; Park, Ga Young et al. (2017) A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med 23:461-471
Werbin, Jeffrey L; Avendaño, Maier S; Becker, Verena et al. (2017) Multiplexed Exchange-PAINT imaging reveals ligand-dependent EGFR and Met interactions in the plasma membrane. Sci Rep 7:12150
Miller, Miles A; Sullivan, Ryan J; Lauffenburger, Douglas A (2017) Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer. Clin Cancer Res 23:623-629
Nagel, Zachary D; Kitange, Gaspar J; Gupta, Shiv K et al. (2017) DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme. Cancer Res 77:198-206
White, Forest M; Wolf-Yadlin, Alejandro (2016) Methods for the Analysis of Protein Phosphorylation-Mediated Cellular Signaling Networks. Annu Rev Anal Chem (Palo Alto Calif) 9:295-315
Wilson, Jennifer L; Dalin, Simona; Gosline, Sara et al. (2016) Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integr Biol (Camb) 8:761-74
Zhao, Boyang; Hemann, Michael T; Lauffenburger, Douglas A (2016) Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends Cancer 2:144-158
Tuncbag, Nurcan; Milani, Pamela; Pokorny, Jenny L et al. (2016) Network Modeling Identifies Patient-specific Pathways in Glioblastoma. Sci Rep 6:28668

Showing the most recent 10 out of 222 publications